

REFERENCES

1. Molijn A, Kleter B, Quint W, Doorn L-Jv. Molecular diagnosis of human papillomavirus (HPV) infections. *J Clin Virol* 2005; 32: S43-51.
2. Parthasarathy B, Xavier B, Atul B, Lynette D, Sharon F, Eduardo LF, et al. Cervical cancer screening in developing countries: report of a WHO consultation. 2000; 1-75.
3. Denny LA, Wright TC Jr. Human papillomavirus testing and screening. *Best Pract Res Clin Obstet Gynaecol* 2005; 19: 501-15.
4. Bozzetti M, Nonnenmacher B, Mielzinska I, Villa L, Lorincz A, Breitenbach V, et al. Comparison between Hybrid Capture II and polymerase chain reaction results among women at low-risk for cervical cancer. *Ann Epidemiol* 2000; 10: 466.
5. Poljak M, Marin IJ, Seme K, Vince A. Hybrid Capture II HPV test detects at least 15 human papillomavirus genotypes not included in its current high-risk probe cocktail. *J Clin Virol* 2002; 25: S89-97.
6. Castle PE, Schiffman M, Burk RD, Wacholder S, Hildesheim A, Herrero R, et al. Restricted cross-reactivity of Hybrid Capture 2 with nononcogenic human papillomavirus types. *Cancer Epidemiol Biomarkers Prev* 2002; 11: 1394-9.
7. Iftner T, Villa LL. Chapter 12: Human papillomavirus technologies. *J Natl Cancer Inst Monogr* 2003; 31: 80-8.
8. Kleter B, van Doorn LJ, Schrauwen L, Molijn A, Sastrowijoto S, ter Schegget J, et al. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. *J Clin Microbiol* 1999; 37: 2508-17.
9. Melchers WJ, Bakkens JM, Wang J, de Wilde PC, Boonstra H, Quint WG, et al. Short fragment polymerase chain reaction reverse hybridization line probe assay to detect and genotype a broad spectrum of human papillomavirus types: clinical evaluation and follow-up. *Am J Pathol* 1999; 155: 1473-8.
10. Quint WG, Scholte G, van Doorn LJ, Kleter B, Smits PH, and Lindeman J. Comparative analysis of human papillomavirus infections in cervical scrapes

and biopsy specimens by general SPF10 PCR and HPV genotyping. *J Pathol* 2001; 194: 51-8.

11. Vernon SD, Unger ER, Williams D. Comparison of human papillomavirus detection and typing by cycle sequencing, line blotting, and hybrid Capture. *J Clin Microbiol* 2000; 38: 651-5.
12. Gravitt PE, Lacey JV, Jr., Brinton LA, Barnes WA, Kornegay JR, Greenberg MD, et al. Evaluation of self-collected cervicovaginal cell samples for human papillomavirus testing by polymerase chain reaction. *Cancer Epidemiol Biomarkers Prev* 2001; 10: 95-100.
13. Lazcano-Ponce E, Herrero R, Muñoz N, Cruz A, Shah KV, Alonso P, et al. Epidemiology of HPV infection among Mexican women with normal cervical cytology. *Inter J Cancer* 2001; 91: 412-20.
14. Bernard H-U. The clinical importance of the nomenclature, evolution and taxonomy of human papillomaviruses. *J Clin Virol* 2005; 32: S1-6.
15. Howley PM and Lowy DR. Papillomaviruses. In: Knipe DM, Peter M, editors. *Fields' virology*. Philadelphia: Lippincott Williams & Wilkins, 2007: 2299-354.
16. Baker TS NW, Olson NH, Cowser LM, Olson C, Brown JC. Structures of bovine and human papillomaviruses-analysis by cryoelectron microscopy and three-dimensional image reconstruction. *Biophysical Journal* 1991; 60:1445-56.
17. Hiller T, Iftner T. The human papillomavirus. In: Prendiville W, Davies P, editors. *Human papillomavirus and cervical cancer*. London: Taylor & Francis, 2004: 11-26.
18. Bonnef W. Papillomavirus. In: Richman DD, Whitley RJ and Hayden FG, editors. *Clinical virology*. Washington DC: ASM Press, 2002: 557-96.
19. Wilson VG, West M, Woytek K, Rangasamy D. Papillomavirus E1 proteins: form, function, and features. *Virus Genes* 2002; 24: 275-90.
20. Hughes FJ, Romanos MA. E1 protein of human papillomavirus is a DNA helicase/ATPase. *Nucl Acids Res* 1993; 21: 5817-23.
21. Thierry F, Howley PM. Functional analysis of E2-mediated repression of the HPV18 P105 promoter. *New Biol* 1991; 3: 90-100.

22. Wilson R, Fehrmann F and Laimins LA. Role of the E1-E4 protein in the differentiation-dependent life cycle of human papillomavirus type 31. *J Virol* 2005; 79: 6732-40.
23. Doorbar J. The papillomavirus life cycle. *J Clin Virol* 2005; 32: 7-15.
24. Bravo IG, Alonso A, Auvinen E. Human papillomavirus type 16 E5 protein. *Papillomavirus Report* 2004; 15: 1-6.
25. Boulet G, Horvath C, Broeck DV, Sahebali S, Bogers J. Human papillomavirus: E6 and E7 oncogenes. *Int J Biochem Cell Biol* 2007; 39: 2006-11.
26. Merck & Co., Inc., USA. 2008. "Natural History of HPV Infection." [Online]. Available <http://images.medscape.com/images/553/264/art-rc553264.fig1.gif> (1 April 2008)
27. Woodman CB, Collins SI and Young LS. The natural history of cervical HPV infection: unresolved issues. *Nat Rev Cancer* 2007; 7: 11-22.
28. Yoshinouchi M, Hongo A, Nakamura K, Kodama J, Itoh S, Sakai H, et al. Analysis by multiplex PCR of the physical status of human papillomavirus type 16 DNA in cervical cancers. *J Clin Microbiol* 1999; 37: 3514-7.
29. Clifford G, Franceschi S, Diaz M, Munoz N, Villa LL. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. *Vaccine* 2006; 24: S26-34.
30. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. *N Engl J Med* 2003; 348: 518-27.
31. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. *CA Cancer J Clin* 2005; 55: 74-108.
32. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi s, Winer R, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. *Int J Cancer* 2007; 121: 621-32.
33. Bao YP, Li N, Smith JS, Qiao YL. Human papillomavirus type distribution in women from Asia: a meta-analysis. *Int J Gynecol Cancer* 2008; 18: 71-9.
34. Schiffman M and Kjaer SK. Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. *J Natl Cancer Inst Monogr* 2003; 31: 14-9.

35. Zheng B. "Improved human papillomavirus DNA typing methods and biology of cervical cancer". Ph. D thesis, Karolinska Institutet, Stockholm, Sweden, 2006.
36. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. *JAMA* 2002; 287: 2114-9.
37. Lowy DR and Schiller JT. Prophylactic human papillomavirus vaccines. *J Clin Invest* 2006; 116: 1167-73.
38. Baseman JG and Koutsky LA. The epidemiology of human papillomavirus infections. *J Clin Virol* 2005; 32: S16-24.
39. Burd EM. Human papillomavirus and cervical cancer. *Clin Microbiol Rev* 2003 ; 16: 1-17.
40. Veress G, Szarka K, Dong XP, Gergely L and Pfister H. Functional significance of sequence variation in the E2 gene and the long control region of human papillomavirus type 16. *J Gen Virol* 1999; 80: 1035-43.
41. Swan DC, Tucker RA, Tortolero-Luna G, Mitchell MF, Wideroff L, Unger ER, et al. Human papillomavirus (HPV) DNA copy number is dependent on grade of cervical disease and HPV type. *J Clin Microbiol* 1999; 37: 1030-4.
42. Zerbini M, Venturoli S, Cricca M, Gallinella G, De Simone P, Costa S, et al. Distribution and viral load of type specific HPVs in different cervical lesions as detected by PCR-ELISA. *J Clin Pathol* 2001; 54: 377-80.
43. Lorincz AT, Castle PE, Sherman ME, Scott DR, Glass AG, Wacholder S, et al. Viral load of human papillomavirus and risk of CIN3 or cervical cancer. *Lancet* 2002; 360: 228-9.
44. Ylitalo N, Sørensen P, Josefsson AM, Magnusson PK, Andersen PK, Pontén J, et al. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. *Lancet* 2000; 355: 2194-8.
45. zur Hausen H. Papillomavirus infections--a major cause of human cancers. *Biochim Biophys Acta* 1996; 1288: F55-78.
46. Klaes R, Woerner SM, Ridder R, Wentzensen N, Duerst M, Schneider A, et al. Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by

- amplification of transcripts derived from integrated papillomavirus oncogenes. *Cancer Res* 1999; 59: 6132-6.
47. Ferenczy A and Franco E. Persistent human papillomavirus infection and cervical neoplasia. *Lancet Oncol* 2002; 3: 11-6.
 48. Gharizadeh B, Zheng B, Akhras M, Ghaderi M, Jejelowo O, Strander B, et al. Sentinel-base DNA genotyping using multiple sequencing primers for high-risk human papillomaviruses. *Mol Cell Probes* 2006; 20: 230-8.
 49. Jacobs MV, Snijders PJ, van den Brule AJ, Helmerhorst TJ, Meijer CJ, Walboomers JM. A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. *J Clin Microbiol* 1997; 35: 791-5.
 50. Castellsagué X and Muñoz N. Chapter 3: Cofactors in human papillomavirus carcinogenesis--role of parity, oral contraceptives, and tobacco smoking. *J Natl Cancer Inst Monogr* 2003; 31: 20-8.
 51. Moreno V, Bosch FX, Muñoz N, Meijer CJ, Shah KV, Walboomers JM, et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. *Lancet* 2002; 359: 1085-92.
 52. Autier P, Coibion M, Huet F and Grivegne AR. Transformation zone location and intraepithelial neoplasia of the cervix uteri. *Br J Cancer* 1996; 74: 488-90.
 53. Muñoz N, Franceschi S, Bosetti C, Moreno V, Herrero R, Smith JS, et al. Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. *Lancet* 2002; 359: 1093-101.
 54. Castellsagué X, Bosch FX and Muñoz N. Environmental co-factors in HPV carcinogenesis. *Virus Res* 2002; 89: 191-9.
 55. Prokopczyk B, Cox JE, Hoffmann D and Waggoner SE. Identification of tobacco-specific carcinogen in the cervical mucus of smokers and nonsmokers. *J Natl Cancer Inst* 1997; 89: 868-73.
 56. Daling JR, Madeleine MM, McKnight B, Carter JJ, Wipf GC, Ashley R, et al. The relationship of human papillomavirus-related cervical tumors to cigarette

- smoking, oral contraceptive use, and prior herpes simplex virus type 2 infection. *Cancer Epidemiol Biomarkers Prev* 1996; 5: 541-8.
57. Parazzini F, Chatenoud L, La Vecchia C, Negri E, Franceschi S, Bolis G. Determinants of risk of invasive cervical cancer in young women. *Br J Cancer* 1998; 77: 838-41.
 58. Schmauz R, Okong P, de Villiers EM, Dennin R, Brade L, Lwanga SK, et al. Multiple infections in cases of cervical cancer from a high-incidence area in tropical Africa. *Int J Cancer* 1989; 43: 805-9.
 59. Smith JS, Herrero R, Bosetti C, Muñoz N, Bosch FX, Eluf-Neto J, et al. Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. *J Natl Cancer Inst* 2002; 94: 1604-13.
 60. Anttila T, Saikku P, Koskela P, Bloigu A, Dillner J, Ikäheimo I, et al. Serotypes of *Chlamydia trachomatis* and risk for development of cervical squamous cell carcinoma. *JAMA* 2001; 285: 47-51.
 61. Calore EE, Pereira SM and Cavaliere MJ. Progression of cervical lesions in HIV-seropositive women: a cytological study. *Diagn Cytopathol* 2001; 24: 117-9.
 62. Herrero R, Brinton LA, Reeves WC, Brenes MM, Tenorio F, de Britton RC, et al. Sexual behavior, venereal diseases, hygiene practices, and invasive cervical cancer in a high-risk population. *Cancer* 1990; 65: 380-6.
 63. Sun XW, Ellerbrock TV, Lungu O, Chiasson MA, Bush TJ and Wright TC Jr. Human papillomavirus infection in human immunodeficiency virus-seropositive women. *Obstet Gynecol* 1995; 85: 680-6.
 64. Palefsky JM and Holly EA. Chapter 6: Immunosuppression and co-infection with HIV. *J Natl Cancer Inst Monogr* 2003; 31: 41-6.
 65. Magnusson PK, Sparén P and Gyllensten UB. Genetic link to cervical tumours. *Nature* 1999; 400: 29-30.
 66. Hildesheim A and Wang SS. Host and viral genetics and risk of cervical cancer: a review. *Virus Res* 2002; 89: 229-40.
 67. Ho GY, Studentsov YY, Bierman R and Burk RD. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. *Cancer Epidemiol Biomarkers Prev* 2004; 13: 110-6.

68. Arbyn M and Dillner J. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening. *J Clin Virol* 2007; 38: 189-97.
69. de Gruijl TD, Bontkes HJ, Stukart MJ, Walboomers JM, Remmink AJ, Verheijen RH, et al. T cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection. *J Gen Virol* 1996; 77: 2183-91.
70. Stern PL. Immune control of human papillomavirus (HPV) associated anogenital disease and potential for vaccination. *J Clin Virol* 2005; 32: S72-81.
71. Adams M, Jasani B and Fiander A. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening. *Vaccine* 2007; 25: 3007-13.
72. Kurman RJ, Henson DE, Herbst AL, Noller KL and Schiffman MH. Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop. *JAMA* 1994; 271: 1866-9.
73. Gaffikin L, Lauterbach M and Blumenthal PD. Performance of visual inspection with acetic acid for cervical cancer screening: a qualitative summary of evidence to date. *Obstet Gynecol Surv* 2003; 58: 543-50.
74. Abulafia O, Pezzullo JC and Sherer DM. Performance of ThinPrep liquid-based cervical cytology in comparison with conventionally prepared Papanicolaou smears: a quantitative survey. *Gynecol Oncol* 2003; 90: 137-44.
75. Guo M, Hu L, Martin L, Liu S, Baliga M and Hughson MD. Accuracy of liquid-based Pap tests: comparison of concurrent liquid-based tests and cervical biopsies on 782 women with previously abnormal Pap smears. *Acta Cytol* 2005; 49: 132-8.
76. Nam JH, Kim HS, Lee JS, Choi HS, Min KW and Park CS. A comparison of modified MonoPrep2 of liquid-based cytology with ThinPrep Pap test. *Gynecol Oncol* 2004; 94: 693-8.
77. Kapala J, Jang D, Patel J, Biers K, Smieja M and Chernesky M. Pap cytopathology and the presence of high-risk human papillomavirus in SurePath liquid preservative and Digene cervical sampler specimens. *J Virol Methods* 2007; 142: 223-5.

78. De Vuyst H, Claeys P, Njiru S, Muchiri L, Steyaert S, De Sutter P, et al. Comparison of pap smear, visual inspection with acetic acid, human papillomavirus DNA-PCR testing and cervicography. *Int J Gynaecol Obstet* 2005; 89: 120-6.
79. Bhatla N, Mukhopadhyay A, Kriplani A, Pandey RM, Gravitt PE, Shah KV, et al. Evaluation of adjunctive tests for cervical cancer screening in low resource settings. *Indian J Cancer* 2007; 44: 51-5.
80. Lörincz AT. Hybrid Capture method for detection of human papillomavirus DNA in clinical specimens: a tool for clinical management of equivocal Pap smears and for population screening. *J Obstet Gynaecol Res* 1996; 22: 629-36.
81. Cope JU, Hildesheim A, Schiffman MH, Manos MM, Lörincz AT, Burk RD, et al. Comparison of the hybrid capture tube test and PCR for detection of human papillomavirus DNA in cervical specimens. *J Clin Microbiol* 1997; 35: 2262-5.
82. Peyton CL, Schiffman M, Lörincz AT, Hunt WC, Mielzynska I, Bratti C, et al. Comparison of PCR- and hybrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies. *J Clin Microbiol* 1998; 36: 3248-54.
83. Peyton CL, Gravitt PE, Hunt WC, Hundley RS, Zhao M, Apple RJ, et al. Determinants of genital human papillomavirus detection in a US population. *J Infect Dis* 2001; 183: 1554-64.
84. Mackay IM, Arden KE and Nitsche A. Real-time PCR in virology. *Nucleic Acids Res* 2002; 30: 1292-305.
85. Hildesheim A, Schiffman MH, Gravitt PE, Glass AG, Greer CE, Zhang T, et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. *J Infect Dis* 1994; 169: 235-40.
86. Tieben LM, ter Schegget J, Minnaar RP, Bouwes Bavinck JN, Berkhout RJ, Vermeer BJ, et al. Detection of cutaneous and genital HPV types in clinical samples by PCR using consensus primers. *J Virol Methods* 1993; 42: 265-79.
87. de Roda Husman AM, Walboomers JM, Hopman E, Bleker OP, Helmerhorst TM, Rozendaal L, et al. HPV prevalence in cytomorphologically normal cervical scrapes of pregnant women as determined by PCR: the age-related pattern. *J Med Virol* 1995; 46: 97-102.

88. Jacobs MV, Snijders PJ, van den Brule AJ, Helmerhorst TJ, Meijer CJ, Walboomers JM. A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. *J Clin Microbiol* 1997 ;35: 791-5.
89. Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlée F, Hildesheim A, et al. Improved amplification of genital human papillomaviruses. *J Clin Microbiol* 2000; 38: 357-61.
90. Kleter B, van Doorn LJ, ter Schegget J, Schrauwen L, van Krimpen K, Burger M, et al. Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. *Am J Pathol* 1998 ; 153:1731-9.
91. Park TC, Kim CJ, Koh YM, Lee KH, Yoon JH, Kim JH, et al. Human papillomavirus genotyping by the DNA chip in the cervical neoplasia. *DNA Cell Biol* 2004; 23: 119-25.
92. Josefsson AM, Magnusson PK, Ylitalo N, Sørensen P, Qvarforth-Tubbin P, Andersen PK, et al. Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. *Lancet* 2000; 355: 2189-93.
93. Tucker RA, Unger ER, Holloway BP and Swan DC. Real-time PCR-based fluorescent assay for quantitation of human papillomavirus types 6, 11, 16, and 18. *Mol Diagn* 2001; 6: 39-47.
94. Strauss S, Desselberger U and Gray JJ. Detection of genital and cutaneous human papillomavirus types: differences in the sensitivity of generic PCRs, and consequences for clinical virological diagnosis. *Br J Biomed Sci* 2000; 57: 221-5.
95. Cubie HA, Seagar AL, McGoogan E, Whitehead J, Brass A, Arends MJ, et al. Rapid real time PCR to distinguish between high risk human papillomavirus types 16 and 18. *Mol Pathol* 2001; 54: 24-9.
96. Hart KW, Williams OM, Thelwell N, Fiander AN, Brown T, Borysiewicz LK, et al. Novel method for detection, typing, and quantification of human papillomaviruses in clinical samples. *J Clin Microbiol* 2001; 39: 3204-12.

97. Lungu O, Wright TC Jr and Silverstein S. Typing of human papillomaviruses by polymerase chain reaction amplification with L1 consensus primers and RFLP analysis. *Mol Cell Probes* 1992; 6: 145-52.
98. Grce M, Husnjak K, Skerlev M, Lipozencić J and Pavelić K. Detection and typing of human papillomaviruses by means of polymerase chain reaction and fragment length polymorphism in male genital lesions. *Anticancer Res* 2000; 20: 2097-102.
99. Arens M. Clinically relevant sequence-based genotyping of HBV, HCV, CMV, and HIV. *J Clin Virol* 2001; 22: 11-29.
100. Gharizadeh B, Oggionni M, Zheng B, Akom E, Pourmand N, Ahmadian A, et al. Type-specific multiple sequencing primers: a novel strategy for reliable and rapid genotyping of human papillomaviruses by pyrosequencing technology. *J Mol Diagn* 2005; 7: 198-205.
101. Altschul SF, Gish W, Miller W, Myers EW and Lipman DJ. Basic local alignment search tool. *J Mol Biol* 1990; 215: 403-10.
102. Kornegay JR, Shepard AP, Hankins C, Franco E, Lapointe N, Richardson H, et al. Nonisotopic detection of human papillomavirus DNA in clinical specimens using a consensus PCR and a generic probe mix in an enzyme-linked immunosorbent assay format. *J Clin Microbiol* 2001; 39: 3530-6.
103. Gravitt PE, Peyton CL, Apple RJ and Wheeler CM. Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method. *J Clin Microbiol* 1998; 36: 3020-7.
104. Coutlée F, Gravitt P, Richardson H, Hankins C, Franco E, Lapointe N, et al. Nonisotopic detection and typing of human papillomavirus DNA in genital samples by the line blot assay. The Canadian Women's HIV study group. *J Clin Microbiol* 1999; 37: 1852-7.
105. van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJ and Snijders PJ. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. *J Clin Microbiol* 2002; 40: 779-87.

106. Klaassen CH, Prinsen CF, de Valk HA, Horrevorts AM, Jeunink MA and Thunnissen FB. DNA microarray format for detection and subtyping of human papillomavirus. *J Clin Microbiol* 2004; 42: 2152-60.
107. Moberg M, Gustavsson I and Gyllensten U. Real-time PCR-based system for simultaneous quantification of human papillomavirus types associated with high risk of cervical cancer. *J Clin Microbiol* 2003; 41: 3221-8.
108. Mayrand MH, Coutlée F, Hankins C, Lapointe N, Forest P, de Ladurantaye M, et al. Detection of human papillomavirus type 16 DNA in consecutive genital samples does not always represent persistent infection as determined by molecular variant analysis. *J Clin Microbiol* 2000; 38: 3388-93.
109. van Doorn LJ, Quint W, Kleter B, Molijn A, Colau B, Martin MT, et al. Genotyping of human papillomavirus in liquid cytology cervical specimens by the PGMV line blot assay and the SPF(10) line probe assay. *J Clin Microbiol* 2002; 40: 979-83.
110. de Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. *Lancet Infect Dis* 2007; 7: 453-9.
111. จตุพล ศรีสมบุญ. ฮิวแมนแพปพิลโลมาไวรัส และมะเร็งปากมดลูก. กรุงเทพฯ: บริษัท ทิมส์ (ประเทศไทย) จำกัด, 2549.